News about the first patient dosing of CDH17 must be imminent…Rebecca mentioned at a recent conference that the CART lab manufacturing process for the 27 yo with stage 4 gastric cancer was well advanced.
This therapy could be practise changing for one of the largest cancer markets with unmet needs….good luck to all involved including patients enrolled in the trial, UPenn clinicians who developed the technology and Chimeric management/shareholders.
Chimeric: Media Thread, page-830
-
- There are more pages in this discussion • 23 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
